Krystal Biotech

KRYS · NASDAQ

$325.42+$5.17 (+1.61%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $320.25

Latest news

NewsOct 15, 12:46 PM ETVandana Singh
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Press releaseOct 15, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Press releaseAug 11, 3:35 PM ETGlobe Newswire
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
NewsAug 3, 7:00 AM ET
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate
Press releaseAug 3, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Press releaseJul 20, 5:42 PM ETPRNewswire
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
Press releaseMay 21, 8:00 AM ETGlobe Newswire
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NewsMay 18, 8:05 AM ET
Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From Birth
Press releaseMay 18, 8:00 AM ETGlobe Newswire
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
NewsMay 15, 2:14 PM ET
MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa
NewsMay 5, 2:19 PM ETAvi Kapoor
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
NewsMay 4, 9:36 AM ET
Krystal Biotech Q1 2026 Earnings Call Transcript
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
NewsMay 4, 7:02 AM ET
Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate
Press releaseMay 4, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Press releaseMar 23, 7:30 AM ETGlobe Newswire
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
NewsFeb 18, 8:01 AM ET
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts
NewsFeb 17, 7:02 AM ET
Krystal Biotech: Q4 Earnings Insights
NewsFeb 17, 7:01 AM ET
Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate
Press releaseFeb 17, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
NewsFeb 17, 6:11 AM ET
Earnings Scheduled For February 17, 2026
Press releaseJan 8, 4:01 PM ETGlobe Newswire
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Press releaseNov 3, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
NewsAug 4, 1:33 PM ETAvi Kapoor
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
Press releaseAug 4, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
Press releaseJun 24, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Press releaseMay 6, 8:00 AM ETGlobe Newswire
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
NewsApr 30, 4:41 PM ETVandana Singh
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Press releaseApr 28, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Press releaseFeb 28, 7:40 AM ETGlobe Newswire
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Press releaseFeb 19, 7:00 AM ETGlobe Newswire
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
Press releaseNov 4, 8:00 AM ETGlobe Newswire
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From Birth

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Q1 2026 Earnings Call Transcript

Earnings Scheduled For May 4, 2026

Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts

Krystal Biotech: Q4 Earnings Insights

Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Earnings Scheduled For February 17, 2026

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates